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Summary
Nanoparticles show several interesting new physical and
biological properties and therefore play an increasing role
in pharmaceutics and medicine. For more than 30 years this
research field has been developing slowly but steadily from
physical and biological interest (bench) to applications in
clinics (bedside). However, many of these particles for bio-
medical applications are still in the pre-clinical or clinical
phase. Combined with drugs or genes these nanoparticles
may change the viability of or the transcription processes
in cells, which make them interesting for the pharmaceut-
ical industry, cell biology and diagnostics.
Because most of the application of superparamagnetic
nanoparticles as therapeutic tool, like non-viral vector, drug
delivery, are still far from clinical use, this review will
concentrate on superparamagnetic nanoparticles as versat-
ile agent for early diagnosis, including the use of such
particles as contrast agent for MR imaging and as vehicle
for the detection of biomarkers.
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hyperthermia; MRI; molecular imaging; diagnostic tool;
biomarker; SPION
Introduction
Nanoparticles show several interesting new physical and
biological properties and therefore play an increasing role
in pharmaceutics and medicine. For more than 30 years this
research field has been developing slowly but steadily from
physical and biological interest (bench) to applications in
clinics (bedside). However, many of these particles for bio-
medical applications are still in the pre-clinical or clinical
phase. Combined with drugs or genes these nanoparticles
may change the viability or the transcription processes in
cells, which make them interesting for the pharmaceutic-
al industry, cell biology and diagnostics. They are: a) of-
fering more specific experiments in the discovery and de-
velopment of a drug as they can interact with cells in an
unspecific or in a specific way [1], b) useful as a versat-
ile tool in early diagnostics, often combined in screening
novel drugs, tracking cells such as stem cells [2, 3] or ad-
sorb at biomarkers, genes etc., and c) may act as a delivery
vehicle for therapeutics which can be modified to be tar-
geted to specific cells or regions of disease and to minimise
secondary systemic negative effects [4] and finally d) act
physically by heating up the surrounding tissue by use of
an external field [5, 6]. Some of these particles may even
serve in a combined way in all three fields and can be use-
ful to determine a certain individual’s susceptibility to dif-
ferent disorders.
Due to their size, their size-dependent properties and
the option of non-invasive application these materials are
promising candidates for research, diagnostic and thera-
peutic applications in various fields such as cancer, neuro-
degenerative diseases (e.g., multiple sclerosis, stroke), in-
flammatory diseases (e.g., rheumatoid arthritis, athero-
sclerosis) and others. Properties only existing on the nano-
scale level, such as the change of ferromagnetic to su-
perparamagnetic behaviour in nanoparticles [7] or the in-
creased intensity and long term stability of fluorescent light
emission of semiconductor crystals [8] (quantum dots), in-
crease the interest of clinicians and industry in these mater-
ials.
Nanoparticles can be purely polymeric or have an in-
organic core that can be coated by inorganic or organic
shells. Those nanoparticles which are used in biomedical
applications include block ionomer complexes, liposomes
[9, 10], polymeric micelles, dendrimers, solid polymeric
nanoparticles designed from synthetic or natural polymers
[11], inorganic nanoparticles based e.g., on iron oxide [12],
nanorods made e.g., by carbon [13] and quantum dots [14]
or metals and metal alloys [15]. Water-soluble synthetic
polymers (dendrimers) are an example of organic nano-
particles tested in pre-clinical models for the delivery of
drugs, genes, and imaging agents as they show a rich ver-
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satility for tailoring their binding properties to several re-
quirements, among them facilitation of cellular uptake of
drugs (e.g., cancer drugs) [16–18]. Magnetic properties,
corrosion resistance and toxicity are the key parameters in
the design of magnetic nanoparticles for medical applica-
tion. Materials that have high saturation magnetisation and
therefore a high magnetic susceptibility are ideal candid-
ates for MRI contrast agents. Common magnetic materi-
als contain Fe, Co, Ni, Mn, Cr or Gd and can be used in
form of metals, metal alloys or metal oxides. Metals and al-
loys, such as Fe, FeCo, FePt, are among magnetic materi-
als, those with the highest magnetisation. Unfortunately all
these materials are susceptible to oxidation and dissolution.
Therefore, toxicity is an important issue and the particles
can only be used if a dense coating on the particle surfaces
is applied. In contrast to metals, metal oxide materials are
generally chemically stable yet have acceptable magnet-
isations. The inorganic particles may have inorganic coat-
ings, for example, of silica, gold or organic coatings such
as those mentioned before. All such particles with sizes
less than about 100 nm (nanoparticles) will be taken up
by mononuclear phagocytes, macrophages and the reticu-
loendothelial system (RES) in the blood and organs if they
are not specially coated by a hydrophilic surface to escape
an uptake within the first minutes after injection. For fur-
ther recognition in specific cells the nanoparticles are func-
tionalised with biological signals, which can be chemically
conjugated onto the surface. Used as vehicles for drug de-
livery these particle systems are finally loaded with thera-
peutic agents whereby the drug-loading capacity depends
on the nanoparticle system. The advantage of modern nan-
oparticle systems is that they can remain in the blood as a
blood pool agent for imaging, or their bioactive component
can be transported to certain organs or tissue important for
therapeutic delivery. These particle systems can also be tar-
geted to the surface of a specific cell or to a specific cell
compartment by entering the cell, a demanding property
for the design and further development of specific drugs,
for gene/plasmid delivery and the deeper knowledge of cell
activities.
Especially superparamagnetic particles based on the
specific physical properties of iron oxide at the size of 5 to
20 nm are a key class of nanoparticles, which have the po-
tential to revolutionise clinical diagnostic and therapeutic
techniques. Widder et al. created the concept of using mag-
netic nano- or microparticles in the late 1970’s [19, 20]. As
most of the application of superparamagnetic nanoparticles
as a therapeutic tool, such as non-viral vector drug delivery,
is still far from clinical use, this review will concentrate
on superparamagnetic nanoparticles as versatile agents for
early diagnosis, including the use of such particles as a con-
trast agent for MR imaging and as a vehicle for the detec-
tion of biomarkers.
Superparamagnetic ironoxide
nanoparticles
Superparamagnetic iron oxide nanoparticles (SPION) be-
long to the class of nanoparticles based on an iron oxide
core and are coated by either inorganic materials (silica,
gold) or synthetic/natural organic materials (phospholipids,
fatty acids, polysaccharides, natural polymers such as dex-
tran or chitosan, biodegradable polymers such as polyethyl-
glycol PEG, non degradable polymers such as like poly-
venylalcohol PVA, peptides or other surfactants) [21–23].
In the last years various classes of superparamagnetic iron
oxide particles have been developed and mentioned in the
widespread literature. These SPIONs are often classified
by their size, which includes the iron oxide core and the
coating/functionalisation, called hydrodynamic diameter,
amongst others by Bowen et al. 2002 [24]; Mornet et al.
2005 [25]; Roch et al. 2005 [26]; Corot et al. 2006 [27],
Thorek et al. 2006 [28]. The largest class can be used orally
and consists of sizes between 300 nm and 3.5 μm; the most
used SPIONs of sizes between 60–150 nm are already used
as MRI agents or are in development for drug delivery [29],
whilst the ultra small SPIONs (also called USPIO) of about
10–40 nm are of interest for gene delivery [30, 31].
Magnetic properties
Magnetic materials can be classified amongst others by
their susceptibility to magnetic fields into diamagnetic ma-
terials with weak repulsion from an external magnetic field
(negative susceptibility), paramagnetic materials showing
small and positive susceptibility, and ferromagnetic mater-
ials exhibiting a large and positive susceptibility to mag-
netic fields, these being known as magnets in daily life
(“horseshoe magnets”). The magnetic properties of materi-
als in the first two classes do not persist after removing the
external magnetic field, while ferromagnetic materials, ex-
hibiting strong attraction to magnetic fields, remain mag-
netised even after the external field is removed. Nano-
particles consisting of iron oxide phases γ-Fe2O3 (Ma-
ghemite) and/or Magnetite (Fe3O4) with sizes <20 nm or
pure iron of 3 nm lose their ferromagnetic behaviour and
show paramagnetic behaviour, which means that no hys-
teresis or magnetism remains after removing the magnetic
field. In contrast to normal paramagnetic material these
materials show a high saturation magnetisation, which
means that a new combination of magnetic behaviour ex-
ists at the nano scale: superparamagnetism. Typically, Ms
values of magnetite nanoparticles are in the range of 30–65
emu/g, which is lower than the 90 emu/g reported for their
ferromagnetic bulk form. The superparamagnetic beha-
viour is characterised by a typical relaxation time τ; the
time which the systems needs to achieve zero magnetisa-
tion after an external magnetic field is switched off:
τ = τ0.exp(KV⁄kBT) (1)
where τ0 is the characteristic time (10–9 s), K is the an-
isotropy energy (20 000 J/m3 for iron oxide) and V is the
volume of the particle: kB is the Boltzmann constant, T is
the temperature. Typical relaxation times for particles with
a diameter of 4 to 10 nm, as used in the case of contrast
agent or for other medical applications, are 10–8 to 10–6 s.
Another effect for which these very small superparamag-
netic particles are of interest is the presence of energy ab-
sorption due to Néel relaxation. As the magnetic domains
fixed within the particles have to be reoriented very quickly
in an alternating (AC) magnetic field, the energy loss of
the particles is used to heat the surrounding environment
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which can, for example, be the cells of a cancer tissue (fur-
ther details on the physical background of superparamag-
netic particles are given by Rosensweig [32]).
Using a permanent magnetic field, the particles are
magnetised up to saturation magnetisation leading to a
magnetic dipol-dipol interaction between the particles in
such a way that the particles are aligned following the field
lines of the permanent external magnet. In a permanent
magnetic field, which shows a filed gradient in z direction,
a force Fm acts on the magnetised particles:
Fm (z) = 4π/3 r3mMs(dBz / dz) (2)
Where rm is the radius of the magnetic part of the
particle, Ms the saturation magnetisation of the particle and
dBz / dz the magnetic flux gradient. This magnetic force
leads to an acceleration of the particles in the direction
of increasing field strengths. In a liquid, the movement is
hindered by a viscous drag (stoke Force, Fs), expressed by
the following equation:
Fs = 6πηrhv (3)
where η is the viscosity of the liquid, rh is the hydro-
dynamic radius of the particle (radius including inorgan-
ic core and the polymer coating) and n is the velocity of
the particles. A large hydrodynamic radius of the particles,
which is often much larger than the magnetic diameter of
the particles, especially if the particles are coated and func-
tionalised with various polymers and biomolecules, makes
it necessary to generate a strong force, i.e., a high gradient
on the magnetic particle to be moved within or against a
fluid pressure such as is present in the lymphatic or blood
system, in tissue like muscles or cartilage or in organs. For
this reason, it is necessary to use high-gradient magnets for
both delivery of therapeutics as well as for separation of
biomolecules and if possible to increase a) the susceptib-
ility of the nanoparticles by the choice of the material and
b) to increase the amount of magnetic particles per delivery
system. Both options are limited, either because only iron
oxide is biocompatible nanostructured material or because
the size of particles may create negative side effects such
as embolic events if it exceeds a certain amount. In case of
intracellular actions like magnetic transfection of a cell, the
particles should even enter the cell, which is only possible
by having small particle sizes [28] or by using transfec-
tion agents [33, 34]. Typical particle sizes for transport and
in-vitro separation are 60 to 150 nm hydrodynamic radius.
Such particles include up to 100 iron oxide crystallites, and
transport velocities of 5 to 20 micrometer per second are
possible.
The magnetic properties of SPION can only be used
properly if the particles are of colloidal stability, which
is an unaccomplished need in application using physiolo-
gical fluids. In such fluids an attractive constant van der
Waals force is present whilst particles, depending on their
coating and functionalisation, show electrostatic and steric
repulsive forces, which vary with the ionic strengths, the
pH-value and the type and conformation of the adsorbed
polymers and biological molecules. In cell media or similar
liquids, which have high ionic strength, only steric stabil-
isation of the coating could avoid agglomeration.But thus
the question is posed about the secondary effects of these
particles on their passage through the human body. Nano-
particles have to be highly specific, efficient, and should
be rapidly internalised by the target cells, which is limited
by several factors [35]: “(i) nanoparticle aggregation (nan-
oparticles have a large surface/volume ratio and tend to ag-
glomerate); (ii) the short half-life of the particles in blood
circulation (when nanoparticles agglomerate, or adsorb
plasma proteins, they are quickly eliminated from the blood
circulation by macrophages of the mononuclear phagocyte
system before they can reach the target cells); (iii) the
low efficiency of the intracellular uptake of nanoparticles;
and (iv) nonspecific targeting.” The coating and function-
alisation of such particles described in the last section is
therefore decisive for their specific application and their
biocompatibility in the human body.
Particles can also agglomerate through the contact with,
for example, proteins and in doing so may provoke changes
regarding cell internalisation or attachment and cytotox-
icity. Therefore synthesis and coating of nanoparticles be-
come a determining step in the further use of nanoparticles
in-vivo and in-vitro. The biocompatibility of such material
is not only related to their nano-size nature, but especially
to their surface properties, which are the determining
factors for cell uptake and cytotoxicity, whereas the type of
particle does not seem to play such an important role (see
Petri-Fink et al. [37]). An overview on some current poly-
mer coating materials is shown in the article of A.K. Gupta
and M. Gupta, 2005 [31], as well as other references deal-
ing with further polymer coatings, amongst others polysac-
charides (dextran, starch and chitosan) [26, 36], polyvinyl
alcohol [37, 38] poly(l-lysine) (PLL) [3], starch derivatives
with phosphate groups binding mitoxantrone as chemo-
therapeutic [39], and inorganic coatings like silica [40] or
gold [41]. All these coatings serve further functionalisation
of the particles by ligands such as, for example, peptide se-
quences conjugated to the nanoparticle surface to facilitate
receptor-mediated endocytosis or phagocytosis [42] or pro-
teins and antibodies to bind to biological receptors [43].
Applications in imaging
Figure 1
Iron oxide nanoparticles as RES contrast media for MRI.
MR images of the hepatic dome before (A) and after injection of
iron oxide nanoparticles (Ferumoxide: 1.4 ml) (B). The lesion
(arrow) is clearly visible after injection of the iron oxide
nanoparticles, but not before. The increase of contrast between the
lesion and the liver is due to a darkening of the normal liver.
Moreover, please note the heterogeneous aspect of the liver,
corresponding to cirrhosis. In this context, the hepatic nodule is
highly suspect of a hepatocellular carcinoma.
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For many years SPIONs have been used in diagnostics
as a contrast agent in magnetic resonance imaging (MRI)
and magnetic resonance angiography (MRA) [27, 44–46].
Various SPION, mostly coated with dextran, are already
on the market or in clinical trials. Several review articles
give an overview of the agents used, such as Corot et al.
2006 [27], who mentions the various polymers used as
coatings, such as different varieties of dextran (dextran,
carboxymethylated dextran, carboxydextran), starch, PEG,
arabinogalactan, glycosaminoglycan, organic siloxane,
Figure 2
In vivo and ex vivo imaging.
In vivo MRI of the infarcted group is presented in (A). The first line
corresponds to a representative rat previously injected with SPION
and clearly shows the appearance over time (day [D] 0 to day 3) of
a hypointense (black) signal in the myocardial infarction area
(arrows). The appearance of the hypointense signal is due to the
superparamagnetic iron oxide. The second line corresponds to a
representative rat without previous injection of SPION. These rats
showed no hypointense signal. Ex vivo MRI (last column) also
depicts a clear hypointense signal in the SPION-injected rat,
whereas no hypointense signal was seen in the non-injected rats
thus confirming the in vivo results. Ex vivo reflectance fluorescence
(B) also confirmed the MR results. A representative image of the
injected group shows a clear increase in fluorescence over time,
whereas the non-injected groups do not show any fluorescent
signal.
Figure 3
Magnetic resonance imaging (MRI) on T2-weighted sequences of
pancreas and tumour.
Preinjection (A) and postinjection (B) of pancreas and tumour. (C)
Image from B at higher magnification. Bombesin-targeted
nanoparticles permit tumour (arrows) to be seen. Arrow indicates
bulk tumour. (D) Postcontrast agent, colorised T2 map of a
pancreas with implanted tumour. Tumour has higher T2s than
normal pancreas. Abbreviations: L, liver; P, pancreas; K, kidney; B,
bowel. (E) Photograph of partially dissected mouse with pancreas
and tumour visible.
sulphonated styrene-divinylbenzen, and gives an overview
on applications showing that the hydrodynamic diameter
of SPION based agents, given intravenously, may vary
between 20 and 180 nm (see also Sun et al. [47]). Another
overview on the application of superparamagnetic iron ox-
ide- based contrast agents has been given by Wang et al.
(2001) [48], who distinguish between agents used as oral
SPION, containing larger particles than injectable agents;
standard SPION, taken up by the RES in liver and spleen
and therefore used for such organs; ultra small SPION with
prolongated blood half time which because of this can be
used for the imaging of lymph nodes and bone marrow;
and monocrystalline SPION, which are much smaller than
other SPION. These particles may be used in cellular and
molecular imaging. Several forms of ultra small superpara-
magnetic iron oxides (USPIO) have undergone clinical tri-
als, one of the most notable being Combidex©, which is in
late stage clinical trials for use in the detection of lymph
node metastases [49]. Various agents are on the market and
act as bowel contrast agents (i.e., Lumiren® and Gastro-
mark®) and liver/spleen imaging agents (i.e., Endorem©
and Feridex IV© [50], or according to Stoll et al. (2009)
[54], especially for USPIO (i.e., Sinerem© (Guerbet) and
Supravist© (Bayer Schering Pharma)), or superparagmet-
ic iron oxide (SPIO) contrast media like Resovist© (Bayer
Schering Pharma).
Contrast agents have to fulfil the requirements of im-
proved enhancement of signals. In contrast to computer
tomography (CT) the magnet resonance imaging (MRI) re-
quires a much lower dose of contrast agent. Negative en-
hancers – like most of the diamagnetic materials – have
only a negligible effect on the MR signals, whilst agents
containing paramagnetic materials like iron or lanthanide
(gadolinium, manganese, dysprosium) show positive en-
hancement by their unpaired electrons resulting in a posit-
ive susceptibility. Iron oxide nanoparticles in a size of 5 to
10 nm induce large magnetic moments altering the magnet-
ic field in a tissue over time and space, and thus create a
large magnetic heterogeneity through which water molec-
ules diffuse. This induces dephasing of the magnetic mo-
ments of protons creating data for MR images [50], and
the T2 relaxation times of water are shortened [52]. It is
the significant capacity of superparamagnetic nanoparticles
to enhance T1 but also T2/T2* relaxation, and by doing
so to reduce the T2/T2* relaxation time (see Wang 2001,
[48]). SPIO particles may decrease T2* by magnetic sus-
ceptibility effect and T2 by dipole-dipole interaction or
scalar effect between protons and magnetic centre [53]. A
large magnetisation difference occurs as a result of the non-
homogeneous distribution of superparamagnetic particles,
which gives rise to local field gradients that accelerate the
loss of phase coherence of the spins contributing to the
MR signal. By this, both T1 and T2 relaxation time is
shortened, however the changes induced are dependent on
the particles used – their size, size distribution and coat-
ing – and their behaviour in acting either at the cell surface
(extracellular) or within the cell (intracellular) [54]. The
signal enhancement by using iron oxide is higher than for
gadolinium chelates [50], the latter belonging to the first
generation of MR contrast agents and acting only extra-
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cellularly [55] as unspecific agents [56], whilst iron oxide
nanoparticles may act in both ways.
The transport of most of the SPION contrast agents is
by intravenous administration, which determines the size of
the nanoparticles. For successful delivery the particles have
to pass the vascular capillary wall. Whilst Gd ion-polymer
complexes, for example, are of small size (≤10 nm), those
of coated iron oxides can be up to 100 nm and therefore act
differently according to the size distribution and the poly-
mer coatings of the agent used. Depending on their size,
charge and the configuration of the coating, these particles
are metabolised by the reticuloendothelial system (RES)
consisting of monocytes and macrophages. These cells, ac-
cumulating in lymph nodes and the spleen as well as in the
liver (Kupffer cells), are favoured for the uptake of SPION
and affect the delivery time and the diffusion to certain tis-
sues. Smaller particles generally circulate longer and are
taken up by cells of the lymphatic system and bone marrow
whilst particles >50 nm are taken up by liver cells [56]. If
particles are not entirely captured by the liver and spleen,
they are widely evaluated as potential markers of inflam-
mation for the diagnosis of inflammatory and degenerat-
ive disorders associated with high macrophage phagocyt-
ic activity such as plaque imaging or brain ischaemia [17].
SPION are also used in liver tumour detection as the tu-
mour lesions exclude the uptake of particles (tissue in MRI
remains bright, because they are lacking Kupffer cells),
whilst the macrophages in the normal liver tissue will take
up the particles and darken the image of the tissue [12].
See also figure 1, reprinted with permission [58]. Beside
the classical fields of SPION use in MRI, imaging of the
gastrointestinal tract (GI tract), liver and spleen imaging,
lymph nodes imaging, blood pool agent [50] and imaging
of inflammatory events (arthritis or other musculoskeletal
disorders [55, 59]), the high sensitivity of iron oxide nan-
oparticles and the capability of such nanoparticles to enter
the cells open novel applications, for example, the tracking
of various kinds of stem cells transplanted into organs such
as the brain [27], to demonstrate macrophage activity with-
in atherosclerotic plaque [60] and in molecular imaging.
Imaging of atherosclerosis and inflammation
Research on the use of SPION for the detection of ath-
erosclerotic plaques by MRI has been undertaken by von
zur Mühlen et al. [61]. Monocytes, as precursor cells of
macrophages, promote atherosclerosis by secreting mediat-
ors and a highly active state of phagocytosis and secretion
of cytokines and chemokines. Before rupture atheroscler-
otic lesions show an accumulation of macrophages. The
phagocytosis of SPION by macrophages may therefore act
as a potential marker of inflammation for plaque imaging.
For the study, MAC-1 expressing Chinese hamster ovary
(CHO) cells, expressing MAC-1 either in a native, low af-
finity state (wildtype, WT) or a high affinity state (GFFKR-
deleted cells, DEL) were used to simulate the type of activ-
ated macrophages found in atherosclerotic plaques. CHO-
cells not expressing MAC-1 were used as controls
(NCHO). These cells were grown for 24 h at 38 °C in a
cell incubator, washed and then either incubated with or
without CD11b-blocking monoclonal antibody 2LPM 19c
and finally amino PVA-SPION were added to the cells and
incubated for another 24 hours. Cell growth and viability
was not influenced by the incubation with SPION (details
of the study are shown in ref. [14]). Those cell lines ex-
pressing the MAC-1–receptor showed higher signal val-
ues compared to natural CHO cells, and the activated re-
ceptor in the DEL cell lines raise the signal extinction up
to four pixels. It could also be shown that MAC-1 ex-
pressing cells incubated with CD11b-antibody constantly
show lower signal extinction than those without CD11b-an-
tibody. The studies identified the integrin MAC-1 (CD 11b/
CD18) as a mediator for the SPION endocytose into mono-
cytes/macrophages and showed that MAC-1 is a central
mediator of inflammation. Dextran-coated particles which
are mostly used as contrast agents are commonly attached
to cells but not taken up by them, while SPION coated
with amino-functionalised polyvinyl alcohols interact with
different cells [62, 23] and therefore underline a receptor-
based uptake of SPION by cells, which could be further
supported through these experiments.
Moreover, mobilisation of monocytes/macrophages in
acute myocardial infarction (MI) has also been proved [63].
Briefly, monocytes/macrophages were loaded by a simple
intravenous injection of SPION. After complete disappear-
ance of the SPION from the blood, an acute MI was created
in rats by ligating a coronary artery. The arrival of mono-
cytes/macrophages was then tracked by magnetic reson-
ance imaging, see figure 2, reprinted with permission [63].
Molecular imaging
Molecular imaging is an integrated discipline defined by
H.R. Herschman (2003) [64] as “non-invasive, quantitative
and repetitive imaging of targeted macromolecules and
biological processes in living organisms. Wickline et al.
(2003) [65] state that molecular imaging can be used “to
improve diagnostic accuracy and sensitivity by providing
an in-vivo analogue in immunocytochemistry or in situ hy-
bridization”. The recent demands in a more “personalised
medicine” demand deeper insight into the whole chain of a
disease, starting with the early detection of the disease and
continuing to a more accurate prognosis, a treatment which
is focused to distinguish between responder and non-re-
sponder and the capability to monitor a therapy und to
better understand the interactions of cells and biomolec-
ules, being the possible determinating step in the treatment.
Therefore, it is important to seek non-invasive methods
by which the effects of diseased tissue on the surround-
ing healthy environment can be visualised and described in
situ and in vivo. In recent years progress has been made
in the field of cellular and molecular imaging technolo-
gies that can depict and identify specific molecules which
are only associated with certain diseases, especially those
which show inflammatory events. Although various ima-
ging modalities are valuable for molecular imaging such as
ultrasound or magnetic resonance (MR) [66] or by nucle-
ar constructs used in PET (see [66]), or by optical imaging
[67], the following description will focus only on MR ima-
ging with SPION. SPION can be functionalised with an-
tibodies or fragments of it, peptides or proteins or small
molecules in a way that they have a high affinity to the tar-
geted cell. For those cases, in which the SPION are used as
“single” or “clusters” of only a few nanoparticles, it is im-
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portant that the longitudinal relaxivity per molecular bind-
ing side for the complex is maximised to receive high con-
trast enhancement even though the number of particles at
the targeted side is low (see [66]). Depending on require-
ments in research it is even possible to visualise single
cells. In comparison with gadolinium containing chelates,
the SPION show a more extensive shortening of T1 and T2
relaxation time, which results in higher sensitivity in ima-
ging when using SPION and the visualisation of single iron
loaded cells at clinical field strengths [54, 68].
Molecular imaging has been applied in a variety of
fields, among them oncology where it has been proved to
enhance the detection of specific tumours by using over-ex-
pressed cellular markers as molecular targets. See figure 3
for an example of pancreas tumour imaging, reprinted with
permission from [69].
Intercellular tracking of biomarkers
Recently, SPION for use in targeting and magnetic extrac-
tion of cellular compounds and their chemical, optical and
physical analysis, including proteomics, were developed
[70]. This use of functional nanoparticles enables the iden-
tification of their specific interaction partners in a physiolo-
gical environment, such as the entire intact cell. Proteom-
ic analysis of diseases, where the immobilised interaction
partner reacts with the target in physiological conditions,
is possible, as well as synthesis of peptide and molecule
libraries for the determination of interaction partners. In
contrast to all other techniques, interaction partners can be
identified in physiological conditions in the cell.
Functionalised nanoparticles smaller than 100 nm car-
rying simultaneously specific organelle addressing pep-
tides, a cyclic RGD peptide and a fluorescent dye are able
to localise specifically at the target site. Exemplarily, nuclei
and mitochondria were studied and in situ affinity chroma-
tography was performed. In order to study particle-organ-
elle interactions, the cell lysate was separated on a mag-
netic separator after the particle incubation on live cells
and lysation of the cells. This cell separator has a strong
magnetic field gradient of several hundred T/m. After pro-
tein electrophoresis, the analysis by mass spectroscopy re-
vealed mitochondrial and nuclear proteins in magnetically
enriched fractions.
To investigate how functionalised SPION interact with
cell organelles, maleimide-PEG-NHS were covalently
bound to amine groups of aminopropylsilica surface of
the particle core, generating PEG-SPION leaving maleim-
ide group of the PEG for coupling of the fluorophores
and peptides via thiol group. In order to assess the effi-
ciency of mitochondrial targeting, three types of function-
alised particles were prepared: coumarin (c[RGDfK-(Ac-
SH)] peptide, mentioned below as cRGD) and/or N-termin-
al 21 residues peptide from mitochondrial 3-oxoacyl-Coen-
zyme A thiolase (mentioned below as MTP) giving rise to
the MTP-SPION, MTP-cRGD-SPION and cRGD-SPION,
respectively. The evaluation of nuclear targeting employed
two types of nanoparticles: the NTP-SPION were function-
alised by FITC and PKKKRKV-GC peptide representing
SV40 large T-antigen nuclear localisation signal peptide
(NTP), and the NTP-cRGD-SPION contained conjugated
cRGD peptide in addition. After the final synthesis step,
functionalised particles showed a size distribution in the
range of 70–100 nm.
After incubation with the nanoparticles, the cells were
lysed and mass spectrometric analysis of the proteins as-
sociated to magnetically sedimented complexes was per-
formed. The proteins detected on the surface of MTP-
cRGD-SPION can be subdivided into several classes: i)
proteins associated directly with the transport of the nan-
oparticles to their target site (heat shock proteins); ii) pro-
teins associated with the transport of the particles to the mi-
tochondrial outer membrane; iii) proteins associated with
the membrane of the mitochondria (e.g., ATP synthase); iv)
proteins associated to the processing of the arriving signal
in the mitochondria (e.g., hsp 60); v) proteins suggested as
associated to the mitochondria, but final proof lacking. Pro-
teins belonging to the second part of glycolysis (GAPDH,
enolase, Pyruvate kinase) were identified proteins. With
this investigation, a novel tool for the investigation of not
only the up-take mechanism but also for biomarker detec-
tion and screening of peptides and drugs was developed.
Conclusion and outlook
Superparamagnetic iron oxide nanoparticles (SPION) are
established contrast agents for a few applications such as
imaging of liver or lymph nodes. The same particles, em-
bedded in larger polymer spheres, are used for in vitro sep-
aration of biomolecules and cells. Other interesting applic-
ations such as molecular imaging enabling early detection
of cancer or other diseases or the more sophisticated trans-
port of drug and genes have shown their feasibility, but
are still far from clinical applications. The main problem,
which slows down the transfer from research to clinic, is
insufficient knowledge on the stability of the particles after
injection, long-term biocompatibility, and even more im-
portant, the need of complex coated particles produced in
a reproducible and cost-efficient manner. The colloidal sta-
bility is strongly influenced by the unspecific adsorption of
proteins during circulation in the blood stream. The invest-
igation of the adsorption is very difficult, because equilibri-
um or steady-state situations in complex systems like blood
are only achieved after long residence times of more than
several hours. This means during the first period where ad-
sorption is observed, a dynamic change of the protein com-
position at the particle surface also occurs. Therefore the
method explained in section four is a very useful tool to
investigate the protein adsorption in a quantitative man-
ner and to compare these results with the observed beha-
viour of the particles. As the interaction of a functional-
ised particle with a certain biofluid depends strongly on
the composition of the particle surface, including target-
ing peptides and the actual composition of the human bio-
fluids, a very complex situation occurs in which the re-
action particle-fluid is very difficult to predict. The key
to further success and also to a personalised medicine is
the development of particles and investigation methods in
welldefined environmental requirements with a focused ap-
plication. A general coating and functionalisation concept
seems, at least today, not to be possible. Therefore close co-
operation between material science, cell and molecular bio-
logy, pharmaceutical and clinical research is the only way
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to enable a clinical application of SPION in the next years,
also including more challenging applications such as mo-
lecular imaging and biomarker detection.
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